At ErythroCure, we work towards developing new therapeutics to treat congenital and acquired disorders of the blood, blood-borne diseases, and blood cell cancers so that no child, woman, or man need suffer from these conditions
Utilizing fundamental insights into the physiology of red and white blood cells, ErythroCure is developing novel treatments for a variety of blood disorders, blood-borne pathogens, and blood cancers.
ErythroCure endeavors to translate new treatment options into clinical practice by advancing lab-based discoveries in basic biology through the drug discovery and development pipeline
We are assembling a world-class team with diverse expertise in blood cell biology, blood-borne pathogens, oncology, and drug development
Data from our anti-malarial Phase 2 clinical trial performed in Vietnam were published in the Journal of Experimental Medicine. These promising results show the strategy of inhibiting host erythrocyte kinases can greatly augment the efficacy of current malaria treatments.
In November 2020, Karson Putt joined ErythroCure as the new COO and interim CEO
Tyrosine kinase inhibitors that halt the progression of malaria was published in the journal PLoS.